BR0207905A - Protamina modificada com imunogenicidade reduzida - Google Patents
Protamina modificada com imunogenicidade reduzidaInfo
- Publication number
- BR0207905A BR0207905A BR0207905-4A BR0207905A BR0207905A BR 0207905 A BR0207905 A BR 0207905A BR 0207905 A BR0207905 A BR 0207905A BR 0207905 A BR0207905 A BR 0207905A
- Authority
- BR
- Brazil
- Prior art keywords
- protamine
- modified
- polypeptides
- reduced immunogenicity
- modification
- Prior art date
Links
- 102000007327 Protamines Human genes 0.000 title abstract 3
- 108010007568 Protamines Proteins 0.000 title abstract 3
- 230000005847 immunogenicity Effects 0.000 title abstract 2
- 229940048914 protamine Drugs 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 230000004048 modification Effects 0.000 abstract 2
- 238000012986 modification Methods 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
"PROTAMINA MODIFICADA COM IMUNOGENICIDADE REDUZIDA". A presente invenção refere-se a polipeptídeos a serem administrados especialmente a seres humanos e em particular para uso terapêutico. Os polipeptídeos são polipeptídeos modificados pelo que a modificação resulta em uma tendência reduzida do polipeptídeo para eliciar uma resposta imune na administração ao indivíduo humano. A invenção em particular refere-se à modificação de protamina para resultar em proteínas de protamina que são substancialmente não-imunogênicas ou menos imunogênicas do que qualquer correspondente não-modificado quando usado in vivo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01105778 | 2001-03-08 | ||
| PCT/EP2002/002241 WO2002069997A1 (en) | 2001-03-08 | 2002-03-01 | Modified protamine with reduced immunogenicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0207905A true BR0207905A (pt) | 2004-07-27 |
Family
ID=8176722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0207905-4A BR0207905A (pt) | 2001-03-08 | 2002-03-01 | Protamina modificada com imunogenicidade reduzida |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20040121443A1 (pt) |
| EP (1) | EP1411969A1 (pt) |
| JP (1) | JP2004520836A (pt) |
| KR (1) | KR20030082961A (pt) |
| CN (1) | CN1494430A (pt) |
| BR (1) | BR0207905A (pt) |
| CA (1) | CA2439929A1 (pt) |
| HU (1) | HUP0303430A3 (pt) |
| PL (1) | PL362699A1 (pt) |
| RU (1) | RU2003129062A (pt) |
| WO (1) | WO2002069997A1 (pt) |
| ZA (1) | ZA200307831B (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010530895A (ja) * | 2007-06-21 | 2010-09-16 | アンジェリカ セラピューティックス，インク． | 修飾毒素 |
| US20090163437A1 (en) * | 2007-10-16 | 2009-06-25 | Regado Biosciences, Inc. | Steady-state subcutaneous administration of aptamers |
| WO2009110944A1 (en) * | 2008-02-29 | 2009-09-11 | Angelica Therapeutics, Inc. | Modified toxins |
| EP2438169B1 (en) | 2009-06-03 | 2017-08-09 | Tobira Therapeutics, Inc. | Nucleic acid modulators of glycoprotein vi |
| WO2011034583A2 (en) | 2009-09-16 | 2011-03-24 | Duke University | Inhibition of endosomal toll-like receptor activation |
| KR20130122632A (ko) | 2010-10-14 | 2013-11-07 | 레가도 바이오사이언스, 인코포레이티드 | Clec-2의 핵산 모듈레이터 |
| ES2686274T3 (es) | 2011-03-18 | 2018-10-17 | Duke University | Péptidos para suprimir la inflamación |
| US9303063B2 (en) | 2011-03-18 | 2016-04-05 | Duke University | Peptide compounds for suppressing inflammation |
| CN102993290B (zh) * | 2012-12-12 | 2014-10-01 | 青岛亚博生物科技有限公司 | 反胶团法分离萃取鱼精蛋白 |
| WO2014150600A2 (en) | 2013-03-15 | 2014-09-25 | Angelica Therapeutics, Inc. | Modified toxins |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2685424B2 (ja) * | 1995-03-13 | 1997-12-03 | 日本水産株式会社 | プロタミンの製造方法 |
| US6624141B1 (en) * | 1999-03-17 | 2003-09-23 | The Regents Of The University Of Michigan | Protamine fragment compositions and methods of use |
-
2002
- 2002-03-01 US US10/471,074 patent/US20040121443A1/en not_active Abandoned
- 2002-03-01 CA CA002439929A patent/CA2439929A1/en not_active Abandoned
- 2002-03-01 PL PL02362699A patent/PL362699A1/xx unknown
- 2002-03-01 EP EP02708339A patent/EP1411969A1/en not_active Withdrawn
- 2002-03-01 CN CNA028060652A patent/CN1494430A/zh active Pending
- 2002-03-01 HU HU0303430A patent/HUP0303430A3/hu unknown
- 2002-03-01 JP JP2002569170A patent/JP2004520836A/ja not_active Withdrawn
- 2002-03-01 RU RU2003129062/15A patent/RU2003129062A/ru not_active Application Discontinuation
- 2002-03-01 KR KR10-2003-7011660A patent/KR20030082961A/ko not_active Application Discontinuation
- 2002-03-01 WO PCT/EP2002/002241 patent/WO2002069997A1/en not_active Application Discontinuation
- 2002-03-01 BR BR0207905-4A patent/BR0207905A/pt not_active IP Right Cessation
-
2003
- 2003-10-07 ZA ZA200307831A patent/ZA200307831B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20030082961A (ko) | 2003-10-23 |
| RU2003129062A (ru) | 2005-04-10 |
| CA2439929A1 (en) | 2002-09-12 |
| EP1411969A1 (en) | 2004-04-28 |
| HUP0303430A3 (en) | 2005-11-28 |
| ZA200307831B (en) | 2004-07-21 |
| CN1494430A (zh) | 2004-05-05 |
| WO2002069997A1 (en) | 2002-09-12 |
| HUP0303430A2 (hu) | 2004-01-28 |
| US20040121443A1 (en) | 2004-06-24 |
| PL362699A1 (en) | 2004-11-02 |
| JP2004520836A (ja) | 2004-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0208041A (pt) | Interferon beta modificado com imunogenicidade reduzida | |
| BR0207016A (pt) | Fator neurotrófico derivado de cérebro humano modificado (bdnf) com imunogenicidade reduzida | |
| BR0207283A (pt) | Anticorpos anti-egfr modificados com imunogenicidade reduzida | |
| BR9712518A (pt) | Polipeptìdeo, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processo para detectar tuberculose em um paciente, e, kit diagnóstico | |
| WO2000034317A3 (en) | Method for reducing immunogenicity of proteins | |
| BR0007840A (pt) | Proteìnas de fusão her-2/neu | |
| BR0207018A (pt) | Leptina modificada com imunogenicidade reduzida | |
| BR0008161A (pt) | Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral | |
| BR0207015A (pt) | Eritropoientina modificada (epo) com imunogenicidade reduzida | |
| BR0207704A (pt) | Alfa interferon modificado com imunogenicidade reduzida | |
| BR9909483A (pt) | Derivados de proteìnas ligantes pneumococcal colina para vacinas | |
| DK382786D0 (da) | Overfladeaktivt rekombinant-alveolarprotein | |
| BR0207905A (pt) | Protamina modificada com imunogenicidade reduzida | |
| BR0207014A (pt) | Antagonista de receptor de interleucina-1 modificada (il-1ra) com imunogenicidade reduzida. | |
| BR0308860A (pt) | Fator viii modificado | |
| BRPI0407533A (pt) | proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas | |
| BR9509172A (pt) | Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica | |
| BR0207705A (pt) | Fator neurotrófico ciliar modificado (cntf) com imonogenicidade reduzida | |
| BR0207945A (pt) | Fator estimulante de colÈnia de macrófagos granulócitos modificados (gm-csf) com reduzida imunogenicidade | |
| BR0211091A (pt) | Métodos para redução de imunogenicidade de polipeptìdeos | |
| BR0207017A (pt) | Fator de crescimento ceratinócito modificado (kgf) com imunogenicidade reduzida | |
| BR0207542A (pt) | Trombopoietina modificada com imunogenicidade reduzida | |
| BR0207020A (pt) | Fator de estimulação de colÈnia por granulócito (g-csf) modificado com imunogenicidade reduzida | |
| BR0208120A (pt) | Insulina modificada com imunogenicidade reduzida | |
| BR0211991A (pt) | HormÈnio do crescimento humano modificado |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5O, 6O E 7O ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009. |